Scholarlink

<p>Osteoporotic vertebral fractures (OVFs) increase mortality and impair patients’ quality of life. Previous studies have focused on the effects of anti-osteoporosis drugs for primary fracture prevention; however, their role in secondary prevention remains insufficiently explored. Since refractures lead to more serious health issues and are strongly associated with prior fractures and low bone mineral density (BMD), effective treatment strategies for patients with existing OVFs are crucial. A systematic search was conducted using PubMED, Cochrane Library, and EMBASE according to PRISMA guidelines. Two reviewers independently selected and assessed relevant studies. A meta-analysis was conducted to examine the effects of anti-osteoporosis medications on refracture prevention in adult patients with existing OVFs. A total of 33 studies were included in the analysis. Compared to the control, bisphosphonates were associated with lower subsequent vertebral fracture (VF) rates at 1&#xa0;year [OR = 0.29, 95% CI = 0.20–0.43], 3&#xa0;years [OR = 0.51, 95% CI = 0.42–0.62], and final follow-up [OR = 0.35, 95% CI = 0.26–0.48]; greater BMD percent changes at 1&#xa0;year [MD = 3.65, 95% CI = 2.63–4.67], 2&#xa0;years [MD = 5.39, 95% CI = 3.87–6.92], and 3&#xa0;years [MD = 5.44, 95% CI = 4.38–6.51]; improved VAS scores at 6&#xa0;months [MD (95% CI) = -0.41 (-0.67, -0.14)] and 12&#xa0;months [MD (95% CI) = -0.92 (-1.25, -0.59)]; and improved ODI scores at 12&#xa0;months [SMD (95% CI) = -1.89 (-3.07, -0.71)]. Teriparatide was associated with lower subsequent VF rates compared to the control [OR = 0.39, 95% CI = 0.16–0.97] and bisphosphonates [OR = 0.41, 95% CI = 0.30–0.56], and led to improved VAS scores at 3&#xa0;months [MD (95% CI) = -1.41 (-2.47, -0.35)] compared to bisphosphonates. Vitamin D improved RMDQ scores at 3&#xa0;months [MD (95% CI) = -1.59 (-2.88, -0.31)] compared to the control. Additionally, romosozumab was associated with lower subsequent VF rates compared to bisphosphonates in patients undergoing vertebral augmentation [OR = 0.21, 95% CI = 0.09–0.51]. Teriparatide may be considered a preferred option for secondary fracture prevention in patients with OVFs. Romosozumab demonstrated potential benefit in patients after vertebral augmentation, although the supporting evidence is limited. Bisphosphonates may remain a reasonable alternative when anabolic agents are unavailable or contraindicated.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年8月22日

查看全文
  • HyungSub Jin,
  • HyungJu Jin,
  • Kyung-Soo Suk,
  • Byung Ho Lee,
  • Si Young Park,
  • Hak-Sun Kim,
  • Seong-Hwan Moon,
  • Sub-Ri Park,
  • Namhoo Kim,
  • Jae Won Shin,
  • Ji-Won Kwon

摘要

Osteoporotic vertebral fractures (OVFs) increase mortality and impair patients’ quality of life. Previous studies have focused on the effects of anti-osteoporosis drugs for primary fracture prevention; however, their role in secondary prevention remains insufficiently explored. Since refractures lead to more serious health issues and are strongly associated with prior fractures and low bone mineral density (BMD), effective treatment strategies for patients with existing OVFs are crucial. A systematic search was conducted using PubMED, Cochrane Library, and EMBASE according to PRISMA guidelines. Two reviewers independently selected and assessed relevant studies. A meta-analysis was conducted to examine the effects of anti-osteoporosis medications on refracture prevention in adult patients with existing OVFs. A total of 33 studies were included in the analysis. Compared to the control, bisphosphonates were associated with lower subsequent vertebral fracture (VF) rates at 1 year [OR = 0.29, 95% CI = 0.20–0.43], 3 years [OR = 0.51, 95% CI = 0.42–0.62], and final follow-up [OR = 0.35, 95% CI = 0.26–0.48]; greater BMD percent changes at 1 year [MD = 3.65, 95% CI = 2.63–4.67], 2 years [MD = 5.39, 95% CI = 3.87–6.92], and 3 years [MD = 5.44, 95% CI = 4.38–6.51]; improved VAS scores at 6 months [MD (95% CI) = -0.41 (-0.67, -0.14)] and 12 months [MD (95% CI) = -0.92 (-1.25, -0.59)]; and improved ODI scores at 12 months [SMD (95% CI) = -1.89 (-3.07, -0.71)]. Teriparatide was associated with lower subsequent VF rates compared to the control [OR = 0.39, 95% CI = 0.16–0.97] and bisphosphonates [OR = 0.41, 95% CI = 0.30–0.56], and led to improved VAS scores at 3 months [MD (95% CI) = -1.41 (-2.47, -0.35)] compared to bisphosphonates. Vitamin D improved RMDQ scores at 3 months [MD (95% CI) = -1.59 (-2.88, -0.31)] compared to the control. Additionally, romosozumab was associated with lower subsequent VF rates compared to bisphosphonates in patients undergoing vertebral augmentation [OR = 0.21, 95% CI = 0.09–0.51]. Teriparatide may be considered a preferred option for secondary fracture prevention in patients with OVFs. Romosozumab demonstrated potential benefit in patients after vertebral augmentation, although the supporting evidence is limited. Bisphosphonates may remain a reasonable alternative when anabolic agents are unavailable or contraindicated.